Chemex Pharmaceuticals announced Wednesday that it hasbegun clinical testing of TCV-309, a topical treatment forpsoriasis.
The Fort Lee, N.J. company (NASDAQ:CHMX) licenses TCV-309, aplatelet activating factor antagonist, from Takeda ChemicalIndustries Ltd. for dermatogical use. This product is beingdeveloped as part of a joint venture between Block Drug Co.Inc. and Chemex Pharmaceuticals Inc. Last December, Chemexfiled an investigational new drug (IND) application with FDA.
(c) 1997 American Health Consultants. All rights reserved.